Patient’s laboratory results on admission and after tocilizumab treatment
| Laboratory parameter . | Normal range . | Results . | ||
|---|---|---|---|---|
| On admit . | 1 wk after TCZ . | 2 wk after TCZ . | ||
| WBC count, ×109/L | 3.5-9.5 | 4.41 | 3.82 | 4.26 |
| Neutrophil count, ×109/L | 1.8-6.3 | 2.82 | 3.11 | 2.09 |
| Lymphocyte count, ×109/L | 1.1-3.2 | 0.89 | 0.58 | 1.18 |
| Hemoglobin, g/L | 130-175 | 127 | 136 | 131 |
| Platelet count, ×109/L | 125-350 | 134 | 156 | 137 |
| ALT, U/L | 5-40 | 41 | 81 | 150 |
| AST, median, U/L | 8-40 | 34 | 53 | 72 |
| Total bilirubin, mmol/L | 5.1-19.0 | 11.6 | 5.8 | 8.5 |
| Creatinine, μmol/L | 44-133 | 84.0 | 69.0 | 82.0 |
| Creatine kinase, U/L | 38-174 | 85 | 80 | 56 |
| Creatine kinase MB, U/L | <6.6 | 0.9 | 0.7 | 0.6 |
| Hypersensitive Tn I, pg/mL | <26.2 | 9.4 | 3.3 | 5.9 |
| Prothrombin time, s | 11.0-16.0 | 13.6 | 13.4 | — |
| aPTT, s | 28.0-43.5 | 31.8 | 35.2 | — |
| Fibrinogen, g/L | 2.0-4.0 | 4.45 | 5.35 | — |
| D-dimer, mg/L | <0.5 | 0.31 | 0.53 | — |
| FDP | <5 | 1.8 | 2.0 | — |
| C-reactive protein, mg/L | <8.0 | 15.4 | 13.85 | 3.14 |
| Procalcitonin, ug/mL | <0.5 | 0.13 | 0.1 | 0.09 |
| Lactate dehydrogenase, U/L | 109-245 | 198 | 210 | 202 |
| β2-Microglobulin, mg/mL | 1.0-3.0 | 1.7 | 1.6 | — |
| Alb, g/L | 33-55 | 33.5 | 36.0 | — |
| IgG, g/L | 7.51-15.6 | 10.2 | 9.97 | — |
| IgA, g/L | 0.82-4.53 | 2.41 | 2.37 | — |
| IgM, g/L | 0.460-3.040 | 0.651 | 0.592 | — |
| Serum κ light chain, mg/L | 1.70-3.70 | 2.5 | 2.3 | — |
| Serum λ light chain, mg/L | 0.90-2.10 | 1.7 | 1.5 | — |
| κ/λ | 1.35-2.65 | 1.47 | 1.53 | — |
| SARS-CoV-2 | ||||
| RNA | Neg | Pos | Neg | Neg |
| Ab-IgG, AU/mL | <10 | 61.41 | 81.56 | 119.67 |
| Ab-IgM, AU/mL | <10 | 166.78 | 109.67 | 24.88 |
| IL-2 level, pg/mL | 0.1-4.1 | 2.77 | 2.67 | 8.02 |
| IL-4 level, pg/mL | 0.1-3.2 | 2.21 | 2.31 | 7.92 |
| IL-6 level, pg/mL | 0.1-2.9 | 121.59 | 57.87 | 117.10 |
| IL-10 level, pg/mL | 0.1-5.0 | 3.55 | 5.26 | 9.61 |
| TNF-α level, pg/mL | 0.1-23.0 | 4.1 | 8.71 | 47.24 |
| CD3+ T cells | 58.17-84.22 | 74.58 | 76.13 | 73.39 |
| CD4+ T cells | 25.34-51.37 | 45.08 | 51.39 | 46.83 |
| CD8+ T cells | 14.23-38.95 | 28.21 | 23.76 | 25.68 |
| CD4/CD8 | 0.41-2.72 | 1.6 | 2.16 | 1.82 |
| Laboratory parameter . | Normal range . | Results . | ||
|---|---|---|---|---|
| On admit . | 1 wk after TCZ . | 2 wk after TCZ . | ||
| WBC count, ×109/L | 3.5-9.5 | 4.41 | 3.82 | 4.26 |
| Neutrophil count, ×109/L | 1.8-6.3 | 2.82 | 3.11 | 2.09 |
| Lymphocyte count, ×109/L | 1.1-3.2 | 0.89 | 0.58 | 1.18 |
| Hemoglobin, g/L | 130-175 | 127 | 136 | 131 |
| Platelet count, ×109/L | 125-350 | 134 | 156 | 137 |
| ALT, U/L | 5-40 | 41 | 81 | 150 |
| AST, median, U/L | 8-40 | 34 | 53 | 72 |
| Total bilirubin, mmol/L | 5.1-19.0 | 11.6 | 5.8 | 8.5 |
| Creatinine, μmol/L | 44-133 | 84.0 | 69.0 | 82.0 |
| Creatine kinase, U/L | 38-174 | 85 | 80 | 56 |
| Creatine kinase MB, U/L | <6.6 | 0.9 | 0.7 | 0.6 |
| Hypersensitive Tn I, pg/mL | <26.2 | 9.4 | 3.3 | 5.9 |
| Prothrombin time, s | 11.0-16.0 | 13.6 | 13.4 | — |
| aPTT, s | 28.0-43.5 | 31.8 | 35.2 | — |
| Fibrinogen, g/L | 2.0-4.0 | 4.45 | 5.35 | — |
| D-dimer, mg/L | <0.5 | 0.31 | 0.53 | — |
| FDP | <5 | 1.8 | 2.0 | — |
| C-reactive protein, mg/L | <8.0 | 15.4 | 13.85 | 3.14 |
| Procalcitonin, ug/mL | <0.5 | 0.13 | 0.1 | 0.09 |
| Lactate dehydrogenase, U/L | 109-245 | 198 | 210 | 202 |
| β2-Microglobulin, mg/mL | 1.0-3.0 | 1.7 | 1.6 | — |
| Alb, g/L | 33-55 | 33.5 | 36.0 | — |
| IgG, g/L | 7.51-15.6 | 10.2 | 9.97 | — |
| IgA, g/L | 0.82-4.53 | 2.41 | 2.37 | — |
| IgM, g/L | 0.460-3.040 | 0.651 | 0.592 | — |
| Serum κ light chain, mg/L | 1.70-3.70 | 2.5 | 2.3 | — |
| Serum λ light chain, mg/L | 0.90-2.10 | 1.7 | 1.5 | — |
| κ/λ | 1.35-2.65 | 1.47 | 1.53 | — |
| SARS-CoV-2 | ||||
| RNA | Neg | Pos | Neg | Neg |
| Ab-IgG, AU/mL | <10 | 61.41 | 81.56 | 119.67 |
| Ab-IgM, AU/mL | <10 | 166.78 | 109.67 | 24.88 |
| IL-2 level, pg/mL | 0.1-4.1 | 2.77 | 2.67 | 8.02 |
| IL-4 level, pg/mL | 0.1-3.2 | 2.21 | 2.31 | 7.92 |
| IL-6 level, pg/mL | 0.1-2.9 | 121.59 | 57.87 | 117.10 |
| IL-10 level, pg/mL | 0.1-5.0 | 3.55 | 5.26 | 9.61 |
| TNF-α level, pg/mL | 0.1-23.0 | 4.1 | 8.71 | 47.24 |
| CD3+ T cells | 58.17-84.22 | 74.58 | 76.13 | 73.39 |
| CD4+ T cells | 25.34-51.37 | 45.08 | 51.39 | 46.83 |
| CD8+ T cells | 14.23-38.95 | 28.21 | 23.76 | 25.68 |
| CD4/CD8 | 0.41-2.72 | 1.6 | 2.16 | 1.82 |
—, not available; Ab, antibody; Alb, albumin; ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; AU, arbitrary units; FDP, fibrin/fibrinogen degradation products; MB, myocardial band; Neg, negative; On admit, on admission; Pos, positive; TCZ, tocilizumab; TNF-α, tumor necrosis factor α; Tn I, troponin I; WBC, white blood cell.